- Home
- BKV vs NAMS Comparison
BKV vs NAMS Comparison
Compare BKV & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BKV | NAMS |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.8B |
| IPO Year | 2022 | 2022 |
Fundamental Metrics
Financial Performance| Metric | BKV | NAMS |
|---|---|---|
| Price | $24.25 | $21.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 16 |
| Target Price | $34.09 | ★ $49.70 |
| AVG Volume (30 Days) | 1.5M | ★ 1.6M |
| Earning Date | 11-09-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 199.00 | 32.81 |
| EPS | ★ 1.11 | N/A |
| Revenue | ★ $893,781,000.00 | $22,503,000.00 |
| Revenue This Year | $25.11 | $30.15 |
| Revenue Next Year | N/A | $384.12 |
| P/E Ratio | $21.82 | ★ N/A |
| Revenue Growth | ★ 47.85 | N/A |
| 52 Week Low | $20.08 | $20.91 |
| 52 Week High | $32.81 | $42.21 |
Technical Indicators
Market Signals| Indicator | BKV | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 57.55 | 34.87 |
| Support Level | $23.26 | $21.02 |
| Resistance Level | $27.40 | $37.26 |
| Average True Range (ATR) | 0.76 | 1.09 |
| MACD | 0.34 | -0.03 |
| Stochastic Oscillator | 91.07 | 8.59 |
Price Performance
Historical ComparisonAbout BKV BKV Corporation
BKV Corp is a growth-driven energy company focused on the development of natural gas-producing assets, the ownership and operation of natural gas-fired power generation assets, and selective accretive acquisitions. The company's core businesses are the production of natural gas and the generation of natural gas-fired power from its owned and operated assets, supported by a closed-loop plan, enabled by its upstream, midstream, power, and CCUS businesses.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.